Apilimod: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 141 patientsc19early.org

Apilimod for COVID-19

Serious outcome risk
Apilimod
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−199%
Mortality (1)−199%
RCTs (1)−199%
Early (1)−199%
00.511.5+
← Apilimod
reduces riskIncreased
risk →
c19early.org
October 2026

Apilimod COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Young (DB RCT)−199%2.99 · 0.12–72.08death1/710/70
Early treatment−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Apilimod
reduces riskApilimod
increases risk →
c19early.org
October 2026

Apilimod COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Young (DB RCT)−199%2.99 · 0.12–72.081/710/70
Early treatment−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Apilimod
reduces riskApilimod
increases risk →
c19early.org
October 2026

Apilimod COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Young (DB RCT)−199%2.99 · 0.12–72.08death1/710/70
Early treatment−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Apilimod
reduces riskApilimod
increases risk →
c19early.org
October 2026

Apilimod COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Young (DB RCT)−109%2.09 · 0.40–11.04no recov.4/642/67
Early treatment−109%2.09 · 0.40–11.044/642/67109% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.39
All studies−109%2.09 · 0.40–11.044/642/67109% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3900.511.52+
Rotate screen for more detailsIncrease width for more details
← Apilimod
reduces riskApilimod
increases risk →
c19early.org
October 2026

Apilimod COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Young (DB RCT)−199%2.99 · 0.12–72.08death1/710/70
Early treatment−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Apilimod
reduces riskApilimod
increases risk →
c19early.org
October 2026

Apilimod COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Young (DB RCT)−199%2.99 · 0.12–72.081/710/70
Early treatment−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−199%2.99 · 0.12–72.081/710/70199% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Apilimod
reduces riskApilimod
increases risk →